The prognostic value of immune checkpoints in oral squamous cell carcinoma.

BACKGROUND Despite the importance of immune checkpoints in immunotherapy, the prognostic value of these molecules remains controversial in oral squamous cell carcinoma (OSCC). We performed a systematic review to investigate the prognostic significance of the immune checkpoints in OSCC. MATERIALS A systematic search was conducted in Ovid Medline, Scopus and Cochrane libraries, and all studies that evaluated the prognostic significance of immune checkpoints in OSCC were systematically retrieved. RESULTS Twelve immune checkpoints/modulators were studied for their prognostic values in OSCC patients between 1985 and 2017. Seven immune checkpoints (FKBP51, B7-H4, B7-H6, ALHD1, PD-L1, B7-H3 and IDO1) were reported to be associated with poor patients' survival in at least one study, and five (CTLA-4, TLT-2, VISTA, PD-L2 and PD-1) did not have a significant prognostic value. PD-L1 results were controversial as it was reported to be associated with both better and worse patients' survival. CONCLUSIONS Even though immune checkpoint markers had high expectation for OSCC prognostication, our systematic review revealed that the majority of them had been studied only once. The other molecules, which had been studied more than once, had controversial findings, except B7-H3.

[1]  N. D’Silva,et al.  Precision Therapy of Head and Neck Squamous Cell Carcinoma , 2018, Journal of dental research.

[2]  R. Pierce,et al.  PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4+ TILs in the Presence of PD-L1+ TAMs. , 2017, Cancer research.

[3]  S. Topalian.  Targeting Immune Checkpoints in Cancer Therapy. , 2017, JAMA.

[4]  Qianming Chen,et al.  The prognostic value of B7‐H6 protein expression in human oral squamous cell carcinoma , 2017, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[5]  Miao-Fen Chen,et al.  Epigenetic therapy regulates the expression of ALDH1 and immunologic response: Relevance to the prognosis of oral cancer. , 2017, Oral oncology.

[6]  P. Hammerman,et al.  Tumor PD-L1 expression is associated with improved survival and lower recurrence risk in young women with oral cavity squamous cell carcinoma. , 2017, International journal of oral and maxillofacial surgery.

[7]  Hyojin Kim,et al.  Clinicopathologic implications of the miR-197/PD-L1 axis in oral squamous cell carcinoma , 2017, Oncotarget.

[8]  T. Salo,et al.  Prognostic biomarkers for oral tongue squamous cell carcinoma: a systematic review and meta-analysis , 2017, British Journal of Cancer.

[9]  O. Stasikowska-Kanicka,et al.  Immunohistochemical Analysis of Foxp3+, CD4+, CD8+ Cell Infiltrates and PD-L1 in Oral Squamous Cell Carcinoma , 2017, Pathology & Oncology Research.

[10]  S. Rottey,et al.  Turning the tide: Clinical utility of PD-L1 expression in squamous cell carcinoma of the head and neck. , 2017, Oral oncology.

[11]  A. Sasaki,et al.  The Immunological Impact of Chemotherapy on the Tumor Microenvironment of Oral Squamous Cell Carcinoma. , 2017, Acta medica Okayama.

[12]  M. Ehrenfeld,et al.  Is There Evidence for the Presence and Relevance of the PD-1/PD-L1 Pathway in Oral Squamous Cell Carcinoma? Hints From an Immunohistochemical Study. , 2017, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[13]  A. Kulkarni,et al.  Selective blockade of B7‐H3 enhances antitumour immune activity by reducing immature myeloid cells in head and neck squamous cell carcinoma , 2017, Journal of cellular and molecular medicine.

[14]  Satoko Matsumura,et al.  PD-L1 Expression Confers Better Prognosis in Locally Advanced Oral Squamous Cell Carcinoma. , 2017, Anticancer research.

[15]  Lei Wu,et al.  Expression of VISTA correlated with immunosuppression and synergized with CD8 to predict survival in human oral squamous cell carcinoma , 2017, Cancer Immunology, Immunotherapy.

[16]  S. Staibano,et al.  FKBP51 Immunohistochemical Expression: A New Prognostic Biomarker for OSCC? , 2017, International journal of molecular sciences.

[17]  Jonathan R. Clark,et al.  Programmed cell death-ligand 1 expression in oral squamous cell carcinoma is associated with an inflammatory phenotype. , 2016, Pathology.

[18]  Lei Wu,et al.  B7-H4 expression indicates poor prognosis of oral squamous cell carcinoma , 2016, Cancer Immunology, Immunotherapy.

[19]  T. Paavonen,et al.  The expression and prognostic relevance of indoleamine 2,3-dioxygenase in tongue squamous cell carcinoma , 2016, Acta oto-laryngologica.

[20]  K. Wolff,et al.  CD274/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity , 2016, Oncotarget.

[21]  Mu-Kuan Chen,et al.  High PD-L1 Expression Correlates with Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma , 2015, PloS one.

[22]  Yih-Leong Chang,et al.  Associations among pretreatment tumor necrosis and the expression of HIF-1α and PD-L1 in advanced oral squamous cell carcinoma and the prognostic impact thereof. , 2015, Oral oncology.

[23]  Chi‐Huey Wong,et al.  Glycoprotein B7-H3 overexpression and aberrant glycosylation in oral cancer and immune response , 2015, Proceedings of the National Academy of Sciences.

[24]  L. Ma,et al.  Expression levels of B7-H3 and TLT-2 in human oral squamous cell carcinoma. , 2015, Oncology letters.

[25]  L. Kowalski,et al.  Gene expression patterns through oral squamous cell carcinoma development: PD-L1 expression in primary tumor and circulating tumor cells , 2015, Oncotarget.

[26]  Ling Wang,et al.  B7‐H3‐mediated tumor immunology: Friend or foe? , 2014, International journal of cancer.

[27]  Deepak Mittal,et al.  New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape. , 2014, Current opinion in immunology.

[28]  H. Morgenstern,et al.  Systematic Reviews and Meta- and Pooled Analyses Cigarette, Cigar, and Pipe Smoking and the Risk of Head and Neck Cancers: Pooled Analysis in the International Head and Neck Cancer Epidemiology Consortium , 2013 .

[29]  T. M. Søland,et al.  Prognostic molecular markers in cancer – quo vadis? , 2013, Histopathology.

[30]  Douglas G Altman,et al.  Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration , 2012, BMC Medicine.

[31]  Y. Cho,et al.  Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma. , 2011, Oral oncology.

[32]  D. von Bubnoff,et al.  Myeloid CD11c+ S100+ dendritic cells express indoleamine 2,3-dioxygenase at the inflammatory border to invasive lower lip squamous cell carcinoma. , 2011, Histology and histopathology.

[33]  F. Kloss,et al.  Expression and prognostic impact of indoleamine 2,3-dioxygenase in oral squamous cell carcinomas. , 2011, Oral oncology.

[34]  H. Friess,et al.  B7-H3 and Its Role in Antitumor Immunity , 2010, Clinical & developmental immunology.

[35]  T. Whiteside,et al.  Immunotherapy for head and neck cancer , 2010 .

[36]  S. Warnakulasuriya.  Global epidemiology of oral and oropharyngeal cancer. , 2009, Oral oncology.

[37]  M. Sydes,et al.  Practical methods for incorporating summary time-to-event data into meta-analysis , 2007, Trials.

[38]  Witold Zatonski,et al.  Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. , 2007, Journal of the National Cancer Institute.

[39]  C. Mathers,et al.  GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer , 2013 .

[40]  C. Leles,et al.  T regulatory cell markers in oral squamous cell carcinoma: Relationship with survival and tumor aggressiveness. , 2010, Oncology letters.

[41]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2009, Journal of clinical epidemiology.

[42]  T. Watts,et al.  Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers and the risk of head and neck cancer: pooled analysis in the international head and neck cancer epidemiology consortium , 2007, BDJ.